A Master Protocol for Biomarker-Based Treatment of AML (The Beat AML Trial)

Trial Profile

A Master Protocol for Biomarker-Based Treatment of AML (The Beat AML Trial)

Phase of Trial: Phase I/II

Latest Information Update: 06 Dec 2017

At a glance

  • Drugs BI 836858 (Primary) ; Samalizumab (Primary) ; Enasidenib; Entospletinib; Gilteritinib
  • Indications Acute myeloid leukaemia
  • Focus Therapeutic Use
  • Acronyms BEAT AML Master Trial
  • Most Recent Events

    • 06 Dec 2017 According to The Leukemia & Lymphoma Society media release, more than 150 patients have been enrolled in the trial till date. University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center has recently joined in the trial and several more cancer centers are expected to join in early 2018.
    • 16 Feb 2017 According to Alexion Pharmaceuticals media release, patients are being dosed in this trial.
    • 13 Dec 2016 According to Alexion Pharmaceuticals' website, the Leukemia and Lymphoma Society is conducting this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top